We are live on ! Find out more
BLRX icon

BioLineRX

29 hedge funds and large institutions have $6.69M invested in BioLineRX in 2021 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 6 increasing their positions, 5 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

230% more capital inflows, than outflows

Capital inflows: $4.3M | Capital outflows: $1.3M

20% more first-time investments, than exits

New positions opened: 6 | Existing positions closed: 5

20% more repeat investments, than reductions

Existing positions increased: 6 | Existing positions reduced: 5

4% more funds holding

Funds holding: 28 → 29 (+1)

2.12% more ownership

Funds ownership: 2.99% → 5.1% (+2.1%)

97% less call options, than puts

Call options by funds: $13K | Put options by funds: $408K

Holders
29
Holders Change
+1
Holders Change %
+3.57%
% of All Funds
0.51%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
6
Increased
6
Reduced
5
Closed
5
Calls
$13​K
Puts
$408​K
Net Calls
-⁠$395​K
Net Calls Change
-⁠$389​K

BLRX Hedge Fund Activity: Q3 2021 in Review

29 of the 5,733 institutional investors tracked by Wall St. Rank reported a position in BioLineRX (BLRX) for Q3 2021, worth a combined $6.69M — up 67% from $4.01M a quarter earlier.

Buyers outnumbered sellers: 6 funds opened new BLRX positions and 5 closed out — a net gain of 1 holder — while 6 added to existing stakes and 5 trimmed.

The largest buyer was ARK Investment Management, opening a new position worth an estimated $3.19M. The largest seller was Parkman Healthcare Partners, cutting an estimated $958K.

  • 29 institutional investors held BioLineRX (BLRX) as of Q3 2021, up from 28 in Q2 2021.
  • Funds reported $6.69M of BioLineRX stock for Q3 2021, up 67% quarter-over-quarter.
  • 6 funds opened new BioLineRX positions in Q3 2021 and 5 closed out, a net change of +1 holder.
  • The largest BioLineRX buyer in Q3 2021 was ARK Investment Management, an estimated $3.19M added.
  • The largest BioLineRX seller in Q3 2021 was Parkman Healthcare Partners, an estimated $958K sold.

Based on aggregated 13F filings for Q3 2021.